These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15322748)

  • 1. Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link?
    Jeffcoate W
    Diabetologia; 2004 Sep; 47(9):1488-92. PubMed ID: 15322748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
    Collin-Osdoby P
    Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC; Heufelder AE; Erben RG
    J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
    Kostenuik PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone cancer pain and the role of RANKL/OPG.
    Clohisy DR; Mantyh PW
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):293-300. PubMed ID: 15615497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis.
    Ohazama A; Courtney JM; Sharpe PT
    J Dent Res; 2004 Mar; 83(3):241-4. PubMed ID: 14981127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC; Schoppet M
    JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magic bullets to kill nasty osteoclasts.
    Khosla S
    Endocrinology; 2005 Aug; 146(8):3233-4. PubMed ID: 16009971
    [No Abstract]   [Full Text] [Related]  

  • 12. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J; Tovar I; Martínez P
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract]   [Full Text] [Related]  

  • 13. [Osteoporosis].
    Chaki O
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
    [No Abstract]   [Full Text] [Related]  

  • 14. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.
    Schoppet M; Al-Fakhri N; Franke FE; Katz N; Barth PJ; Maisch B; Preissner KT; Hofbauer LC
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4104-12. PubMed ID: 15292354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minireview: the OPG/RANKL/RANK system.
    Khosla S
    Endocrinology; 2001 Dec; 142(12):5050-5. PubMed ID: 11713196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.
    Gravallese EM; Galson DL; Goldring SR; Auron PE
    Arthritis Res; 2001; 3(1):6-12. PubMed ID: 11178122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of bone cell development and function: implication for renal osteodystrophy.
    Disthabanchong S; González EA
    J Investig Med; 2001 May; 49(3):240-9. PubMed ID: 11352181
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
    Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin.
    Mancini L; Moradi-Bidhendi N; Brandi ML; Perretti M; MacIntyre I
    Biochem Biophys Res Commun; 2000 Dec; 279(2):391-7. PubMed ID: 11118297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.